84 tablets – 10/2019
90 tablets – 02/2021
100 tablets – 04/2020
1 tablet contains 250 mg of flutamide
Flutamide is a nonsteroidal drug with anti-androgenic action. The mechanism of action involves the inhibition of androgen capture and/or inhibition of androgen binding in cell nuclei of tissues-targets. Its ability to inhibit the action of testosterone at the cellular level is to complement the medical “castration” caused by agonists of luteinizing hormone — releasing hormone (LHRH). Target organs of pharmacological action of flutamide are the prostate and seminal vesicles. Flutamid does not possess estrogenic, anti-estrogenic and progestogenic antigestagen activity.
Treatment of patients with advanced forms of prostate cancer, which shows suppression of the action of testosterone
Initial therapy in combination with an analogue of LH/RH or combined with orchiectomy (complete androgen blockade)
Treatment of patients undergoing therapy with the use of an analogue of LH/RH or who have carried out surgical Ablatio testis
Treatment patients who appealed to endocrine forms of therapy or for whom such therapy is not tolerated, but because of the need which they are shown
Flutamide is contraindicated in patients with hypersensitivity to flutamide or other ingredients.
Precautions: patients with impaired liver function, patients with tendency to thrombosis and in cardiovascular diseases.
Method of application and doses
Flutamid appoint 1 tablet 3 times a day every 8 hours. In the case of achieving the positive effect of the drug is administered until signs of progression of the neoplastic disease.
In the case of combined therapy with agonists lgrg, both medications can be prescribed simultaneously or the reception of flutamide begin three days before the first dose of agonist LHRH.
Treatment flutamide should be under the control of the level of liver enzymes in the blood (appropriate laboratory tests should be performed 1 time per month during the first 4 months and then regularly). In case of increase of hepatic enzymes level by 2-3 times in comparison with the upper limit of normal values and/or the appearance of jaundice in the absence of liver metastases the use of flutamide should be discontinued. Patients should immediately consult a doctor when the first symptoms of liver dysfunction such as pruritus, dark urine, nausea, vomiting, persistent loss of appetite, yellowing of the skin or whites of the eyes, pain in the right upper quadrant or prepodobnyi symptoms.
Due to the possible increase in anticoagulant effect of the simultaneous use of warfarin and flutamide, the dose of the anticoagulant should be selected under the control of prothrombin time.
In view of the possible increase in anticoagulant effect of the simultaneous use of warfarin and flutamide, the dose of the anticoagulant should be selected under the control of prothrombin time.
Store at temperatures below 25 °C, protected from light.